Genetic Re-programming of Stem Cells to Fight Cancer
There are few options for patients whose cancers have metastasized due to resistance to current therapies. This team is using gene editing technology to modify a patient’s own immune system cells and blood-forming stem cells with the aim of creating a continuous supply of immune cells that can recognize and attack hard-to-treat cancers.
Primary: Safety and feasibility. Secondary: Persistence of gene-marked anti-cancer immune cells
News about this clinical trial:
- UCLA opens first engineered blood stem cell clinical trial for cancers with the NY-ESO-1 tumor marker